December 26, 2025 10:27 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion | Delhi erupts over lynching of Hindu man in Bangladesh; protest outside High Commission | Targeted killing sparks global outrage: American lawmakers condemn mob lynching of Hindu man in Bangladesh | Assam on a ‘powder keg’: Himanta Biswa Sarma flags demographic shift, Chicken’s Neck fears | Bangladesh on edge: Student leader shot as pre-poll violence deepens after Hadi killing | Historic deal sealed: India, New Zealand sign landmark Free Trade Agreement in record time | Supreme court snubs urgent plea to stop PMO’s chadar offering at Ajmer Sharif
Covaxin | Bharat Biotech
Image Credit: Pixabay

Bharat Biotech to start Covaxin trials in 2-18 age grp in next 10-12 days: Niti Aayog member

| @indiablooms | May 19, 2021, at 02:13 am

New Delhi/IBNS: Bharat Biotech will launch the phase II and III clinical trials for Covaxin in children between the ages of 2 to 18 years in the next 10-12 days,  Dr VK Paul, member (health) of Niti Aayog, said on Tuesday.

"Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days," Paul said during a press conference, reported Hindustan Times.

On May 11, Drugs Controller General of India's (DCGI) gave its nod to conduct clinical trials in children.

DGCI gave the permission based on the recommendations by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation’s (CDSCO), which signalled the trial subject to certain conditions, the report said.

In February last, Bharat Biotech had approached the DGCI seeking permission for conducting clinical trials in children in the 5-18 age group.

However, the central drug regulator had rejected the proposal and asked the firm to come up with data showing the vaccine's efficacy in adults first.

The US and Canada have already approved the Pfizer-BioNTech shots for ages 12-15 and started vaccinating them from May 14.

Canada,too, had approved the Pfizer jabs for this age group on May 5.

Meanwhile, the European Medical Agency is also measuring the efficacy of the use of Pfizer vaccines in beneficiaries below 18 years of age.

The clinical trials in India are expected to be conducted in 525 participants at multiple hospitals, the HT report said.

AIIMS chief Dr Randeep Guleria had stated the need for quick data and risk-benefit analysis of the Covid-19 vaccine in children. 

Experts across the world have been appealing to the governments across the world to vaccinate children for the schools to reopen safely.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.